Market Cap 1.83B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 72.00
Profit Margin -19.72%
Debt to Equity Ratio -1.81
Volume 2,416,000
Avg Vol 4,874,286
Day's Range N/A - N/A
Shares Out 209.25M
Stochastic %K 9%
Beta 1.04
Analysts Strong Sell
Price Target $16.73

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
stonedbunny
stonedbunny Jul. 12 at 10:14 PM
$BCRX Time for Stoney to shine
1 · Reply
lookingaroundhere
lookingaroundhere Jul. 12 at 12:56 AM
$BCRX News today about an acquisition of Galidesivir https://biotechdispatch.com.au/news/island-expands-portfolio-with-the-acquisition-of-antiviral
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 7:25 PM
$BCRX Time to load up on this one! I added a few more
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 6:43 PM
$BCRX This is a waiting game now! https://youtu.be/_wyWfklvNHc Waiting by the shoreline In Somalia for your reply I need you to come see me That's no lie The guns are getting closer The sweat pours like dew That fell from the trees in Tripoli In the spring I'm white hot I can't take it anymore I'm white hot By the Somalian shore Yes, I'm burning to the core I need rain
0 · Reply
SpencerF
SpencerF Jul. 11 at 5:55 PM
$BCRX grand final bottom?
0 · Reply
Thinkingman91
Thinkingman91 Jul. 11 at 5:44 PM
$BCRX I’m like geico but for your monies
1 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 5:14 PM
$BCRX When I was a young boy, my dad said to me we’re going fishing 🎣 son… Go dig some worms for us…when we were fishing I caught a small fish, I was proud to have caught it…then my dad started cutting it up into pieces, I was upset at what he was doing with my prized small fish…then he baited my line with bigger pieces of cut up fish parts…then he said let’s start fishing 🎣 now! I learned a big lesson then, you sacrifice a few small ones to catch the bigger ones! That’s what is going on here now, they sell sacrifice a few to get the price down lower and wait to catch the bigger ones or the many… Hold cycle a few, add when you can! Best to all here.
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 5:04 PM
$BCRX wow this stayed at $8.74 for the longest time! Could the bottom now soon be in…? Pretty quiet around here…are we still good to meet in Las Vegas after this one is sold?
1 · Reply
clownmarket
clownmarket Jul. 11 at 4:34 PM
$BCRX Gentle reminder that if you plot patient growth against time for Orladeyo, you get a (lopsided) smiley face - patient growth in 2024 accelerated to match the first year of launch - then in May they told us that patient growth in Q1 2025 was stronger than any quarter in 2024 This is not REVENUE growth, which is affected by the free-to-paid improvements (where most of the guidance raises come from) and annual price increases, but underlying PATIENT growth As another gentle reminder, in 2023 they were forecasting LINEAR patient growth (on average) of ~200 patients per year to hit the peak target. Some people confused this with linear revenue growth and thought hitting 1bn was therefore impossible. That was the wrong way to think about it, and in fact linear patient growth in this sector gives you compounding revenue growth. But patient growth is accelerating. What do you think will happen with revenue? Think about rates of change.
4 · Reply
maphere
maphere Jul. 11 at 3:50 PM
$CLSD $BCRX Biocryst has an abstract at an upcoming eye conference on July 30th. The presentation is made by a high-end retinal specialist, Dr. Dhoot. Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model https://www.asrs.org/content/documents/detailed-schedule-with-running-changes_july-10.pdf
6 · Reply
Latest News on BCRX
ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 4 weeks ago

ORLADEYO® (berotralstat) Approved in Colombia


BioCryst to Present at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst to Present at Upcoming Investor Conferences


BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 2:05 PM EDT - 2 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy


BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 2 months ago

BioCryst Appoints Steve Frank to Board of Directors


BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 2 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5


BioCryst to Present at Upcoming Investor Conference

Apr 2, 2025, 4:01 PM EDT - 3 months ago

BioCryst to Present at Upcoming Investor Conference


BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 4 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started


BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 5 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal


BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 9, 2024, 1:47 PM EST - 7 months ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy


BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 18, 2024, 2:00 AM EST - 8 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland


ORLADEYO® (berotralstat) Approved in Peru

Jul 9, 2024, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Peru


ORLADEYO® (berotralstat) Approved in Mexico

May 13, 2024, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Mexico


stonedbunny
stonedbunny Jul. 12 at 10:14 PM
$BCRX Time for Stoney to shine
1 · Reply
lookingaroundhere
lookingaroundhere Jul. 12 at 12:56 AM
$BCRX News today about an acquisition of Galidesivir https://biotechdispatch.com.au/news/island-expands-portfolio-with-the-acquisition-of-antiviral
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 7:25 PM
$BCRX Time to load up on this one! I added a few more
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 6:43 PM
$BCRX This is a waiting game now! https://youtu.be/_wyWfklvNHc Waiting by the shoreline In Somalia for your reply I need you to come see me That's no lie The guns are getting closer The sweat pours like dew That fell from the trees in Tripoli In the spring I'm white hot I can't take it anymore I'm white hot By the Somalian shore Yes, I'm burning to the core I need rain
0 · Reply
SpencerF
SpencerF Jul. 11 at 5:55 PM
$BCRX grand final bottom?
0 · Reply
Thinkingman91
Thinkingman91 Jul. 11 at 5:44 PM
$BCRX I’m like geico but for your monies
1 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 5:14 PM
$BCRX When I was a young boy, my dad said to me we’re going fishing 🎣 son… Go dig some worms for us…when we were fishing I caught a small fish, I was proud to have caught it…then my dad started cutting it up into pieces, I was upset at what he was doing with my prized small fish…then he baited my line with bigger pieces of cut up fish parts…then he said let’s start fishing 🎣 now! I learned a big lesson then, you sacrifice a few small ones to catch the bigger ones! That’s what is going on here now, they sell sacrifice a few to get the price down lower and wait to catch the bigger ones or the many… Hold cycle a few, add when you can! Best to all here.
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 5:04 PM
$BCRX wow this stayed at $8.74 for the longest time! Could the bottom now soon be in…? Pretty quiet around here…are we still good to meet in Las Vegas after this one is sold?
1 · Reply
clownmarket
clownmarket Jul. 11 at 4:34 PM
$BCRX Gentle reminder that if you plot patient growth against time for Orladeyo, you get a (lopsided) smiley face - patient growth in 2024 accelerated to match the first year of launch - then in May they told us that patient growth in Q1 2025 was stronger than any quarter in 2024 This is not REVENUE growth, which is affected by the free-to-paid improvements (where most of the guidance raises come from) and annual price increases, but underlying PATIENT growth As another gentle reminder, in 2023 they were forecasting LINEAR patient growth (on average) of ~200 patients per year to hit the peak target. Some people confused this with linear revenue growth and thought hitting 1bn was therefore impossible. That was the wrong way to think about it, and in fact linear patient growth in this sector gives you compounding revenue growth. But patient growth is accelerating. What do you think will happen with revenue? Think about rates of change.
4 · Reply
maphere
maphere Jul. 11 at 3:50 PM
$CLSD $BCRX Biocryst has an abstract at an upcoming eye conference on July 30th. The presentation is made by a high-end retinal specialist, Dr. Dhoot. Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model https://www.asrs.org/content/documents/detailed-schedule-with-running-changes_july-10.pdf
6 · Reply
tylax30
tylax30 Jul. 11 at 2:39 PM
$BCRX there’s always weeks to months of pain here before a short lived move up. One day that move up will not be short lived and I will be here for it. Let’s see what happens at earnings.
3 · Reply
Clifden
Clifden Jul. 11 at 2:15 PM
$BCRX Sometimes the chronic complainers are smarter than the LT pumpers !! All the best !!
2 · Reply
WKNDatBERNIES
WKNDatBERNIES Jul. 11 at 2:08 PM
$BCRX wtf
0 · Reply
BirdStar
BirdStar Jul. 11 at 2:05 PM
$BCRX I have muted all the chronic complainers at this point, but I would bet there's a few bitching and moaning this morning.
0 · Reply
Dpst2022
Dpst2022 Jul. 11 at 1:47 PM
$BCRX Where are the hardcore loyal cheerleaders today that worship stonehouse for his performance
0 · Reply
Iwillbuy
Iwillbuy Jul. 11 at 1:34 PM
$BCRX amazing how they can move this where ever they want? Yet the mm don’t work act in unison…yeah my ass they don’t! This is one is being courted for marriage soon!
2 · Reply
DavidDayTrade
DavidDayTrade Jul. 11 at 1:30 PM
$BCRX WILL BACK TO 11$ SOON, IMO
0 · Reply
ChillPill1972
ChillPill1972 Jul. 11 at 1:05 PM
$BCRX BioCryst will present the following three abstracts in a poster session on Friday, July 11 from 12:30-1:30 p.m. ET: Patient Perspectives on the Importance of HAE Treatments; Poster #25 Burden of Treatment for Pediatrics Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers; Poster #4 HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P; Poster #13 (encore from AAAAI / WAO 2025) BioCryst President and CEO Jon Stonehouse will also address members of the HAE community in attendance in a corporate presentation during the Summit.
2 · Reply
Andretorre94
Andretorre94 Jul. 11 at 12:54 PM
0 · Reply
Swiftytwits
Swiftytwits Jul. 11 at 12:15 PM
0 · Reply
Clifden
Clifden Jul. 11 at 12:11 PM
$BCRX Sold at 8.10 last year and sleeping a lot better. You should short the maker of Ambien as I no longer consume it 🤪. I still believe in this ticker but Jon should go !!
0 · Reply
Dpst2022
Dpst2022 Jul. 11 at 9:36 AM
$BCRX Galidesivir was "designed for the covid pandemic" to paraphrase the CEO but instead got sold for pennies to random nobodies.
1 · Reply